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We describe the characterization of a foot-and-mouth 
disease (FMD) serotype A virus responsible for recent out-
breaks of disease in Egypt. Phylogenetic analysis of VP1 
nucleotide sequences demonstrated a close relationship to 
recent FMD virus isolates from East Africa, rather than to 
viruses currently circulating in the Middle East.
F
oot-and-mouth disease (FMD) is caused by 7 immu-
nologically distinct serotypes, O, A, C, Asia 1, South 
African Territories (SAT) 1, SAT 2, and SAT 3, which be-
long to the species Foot-and-mouth disease virus (genus 
Aphthovirus, family Picornaviridae). Several of these sero-
types circulate currently or periodically in the Middle East 
and North Africa (1). In Egypt, routine prophylactic vacci-
nation has been conducted with a locally produced serotype 
O vaccine. The last outbreak of serotype O was in June 
2000, and other serotypes have not been reported since 
1972 when serotype A occurred (2). This report describes 
an FMD serotype A virus responsible for recent outbreaks 
of disease in Egypt. 
Clinical cases of FMD were ﬁ  rst recognized on Jan-
uary 22, 2006, on a cattle farm at El Etehad in Ismailia, 
northeastern Egypt (Figure 1). Samples were submit-
ted for laboratory investigation and serotype determina-
tion by using virus isolation, antigen ELISA, and reverse 
transcription–PCR (RT-PCR). Initial testing with antigen 
ELISA and RT-PCR assays suggested that multiple FMD 
virus (FMDV) serotypes may have been involved in the 
outbreak (data not shown), although only type A was later 
conﬁ  rmed. On February 15, 2006, the Agriculture Minis-
try in Egypt notiﬁ  ed international public health authori-
ties (by reporting to the World Organization for Animal 
Health [OIE]) of 6 outbreaks of FMDV caused by sero-
type A in Ismailia and 12 additional outbreaks in 7 other 
Egyptian governorates: Alexandria (2 outbreaks), Behera 
(1 outbreak), Cairo (1 outbreak), Dakahlia (1 outbreak), 
Dumyat (5 outbreaks), Fayum (1 outbreak), and Menoﬁ  a 
(1 outbreak). By April 6, 2006, 34 outbreaks of disease had 
been reported that affected >7,500 animals and involved 
an additional governorate (Kalubia). Most (96.7%) clini-
cal FMD cases involved cattle; 411 cattle (mainly calves) 
reportedly died. Attempts to control the outbreaks were 
hampered by lack of an appropriate vaccine and concurrent 
outbreaks of highly pathogenic avian inﬂ  uenza. FMD be-
came widespread in Egypt, with the following numbers of 
animals affected per month: 6,189 (January), 1,858 (Febru-
ary), 3,035 (March), 401 (April), and 297 (May). A locally 
produced bivalent FMDV vaccine, containing both O1 and 
A/Egypt/2006 isolates, was released in mid-May 2006 for 
the ﬁ  rst time in Egypt. No new cases have been reported 
since July 2006.
The Study
Clinical material from 5 cases (collected from 3 sepa-
rate locations in Egypt; Table 1) was sent to the Food and 
Agricultural Organization of the United Nations (FAO) 
World Reference Laboratory for FMD (WRLFMD) at the 
Institute for Animal Health, Pirbright, United Kingdom, for 
conﬁ  rmatory diagnosis and characterization of the caus-
ative FMDV strain(s). The possibility that these samples 
contained multiple FMDV serotypes was also investigated. 
FMDV isolates causing cytopathic effects in primary bo-
vine thyroid (BTy) cell cultures were generated from all 
samples. The cell culture–grown virus isolates and original 
clinical submissions were identiﬁ  ed as FMDV serotype A 
by antigen-detection ELISA (3).
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Figure 1. Locations and numbers of cases in the initial outbreaks of 
foot-and-mouth disease, Egypt, 2006. DISPATCHES
Total RNA was extracted from the ﬁ  rst virus passage 
on BTy cells by using RNeasy kits (QIAGEN, Crawley, 
UK) for all 5 samples (EGY/1/2006–EGY/5/2006) (4). The 
complete VP1 region of the genome was ampliﬁ  ed by RT-
PCR by using 2 primer sets (A-1C562F/EUR-2B52R and 
A-1C612F/EUR-2B52R; Table 2) and the following ther-
mal proﬁ  le: 42°C for 30 min; 94°C for 5 min; 35 cycles of 
94°C for 60 s, 55°C for 60 s, and 72°C for 90 s, followed by 
a ﬁ  nal extension of 72°C for 5 min. The sequence of each 
amplicon was determined by cycle sequencing as previ-
ously described (4) but with the primers NK72, A-1C612F, 
and A-1D523R (Table 2). An unrooted neighbor-joining 
tree was constructed by using MEGA version 3.1 (5). The 
robustness of the tree topology was assessed with 1,000 
bootstrap replicates as implemented in the program. Ad-
ditionally, maximum parsimony (MEGA 3.1), minimum 
evolution (MEGA 3.1), and maximum likelihood (TREE-
PUZZLE 5.2; [6]) trees were constructed; all 4 methods 
gave similar tree topologies (data not shown). Egyptian 
sequences shared a closer phylogenetic relationship with 
recent and historical isolates from East Africa rather than 
with contemporary serotype A viruses emerging from Iran, 
currently circulating in the Middle East and European Tur-
key (Figure 2).
Other conventional “typing” PCRs were performed to 
investigate whether additional FMDV serotypes were pres-
ent in these samples. A multiplex agarose gel–based RT-
PCR that targeted VP1 of O, A, C, and Asia 1 (primers P33, 
P38, P87–92, P40, P74–77) (7) generated a single band 
corresponding to the size expected (702 bp) for serotype A 
for all 5 samples (data not shown). In addition, a cocktail of 
primers (P1, P126, P150–153, P130, P159–161, P168–170) 
(7) recognizing VP1 of SAT1–3 serotypes did not show any 
bands after RT-PCR with these samples. However, ampli-
cons of correct size (715 bp) were obtained after RT-PCR 
with samples EGY/1/2006, EGY/3/2006, and EGY/5/2006 
when an additional primer set for SAT 1–3 VP1 (1D209F/
2B208R) was used (8). Subsequent analysis of these SAT 
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Table 1. Foot-and-mouth disease type A viruses examined in the study 
WRLFMD ref. no. 
or virus name*  Location Date collected Species
GenBank
accession no. 
A/ARG/2000 Argentina 2000 Not known  AY593782 
A/Trenquelauquen/ 
ARG/2001 
Trenquelauquen, Argentina  Mar 31, 2001  Bovine AY593786 
A24/Cruzeiro/BRA/55 Cruzeiro, Brazil 1955 Bovine AJ251476
A/CAR/15/2000 Lahore Vina, Vina, Adamawa, Cameroon  2000 Bovine EF208755
A/EGY/1/72  Alexandria, Egypt  May 13, 1972  Bovine EF208756
A/EGY/1/2006  Ismailia, Egypt  Feb 9, 2006  Bovine EF208757
A/EGY/2/2006  Ismailia, Egypt  Feb 9, 2006  Bovine EF208758
A/EGY/3/2006  Ismailia, Egypt  Feb 9, 2006  Bovine EF208759
A/EGY/4/2006  Fayoum, Egypt  Feb 16, 2006  Bovine EF208760
A/EGY/5/2006  Domiat, Egypt  Feb 19, 2006  Bovine EF208761
A/ETH/7/92 Shena, Ethiopia  Oct 3, 1992  Bovine EF208765
A/ETH/1/94 Highland areas of Eastern Ethiopia  Feb 2, 1994  Bovine EF208766
A/ETH/23/94 Nazret, East Shoa, Ethiopia  Mar 9, 1994  Not known  EF208767
A5/Allier/FRA/60 Allier, France 1960 Bovine AY593780 
A/GAM/44/98 Gambia Feb 4, 1998  Not known  EF208768
A10/HOL/42  Groot-Ammers, the Netherlands  1942 Bovine M20715
A/IND/17/77† Tamil Nadu, India  1977 Bovine AF204108
A/IRN/2/87 Mardabad, Kardaj, Tehran, Iran  Mar 11,1987  Bovine EF208770
A/IRN/1/96 Zarnan, Shahriar, Tehran, Iran  Nov 13, 1996  Bovine EF208771
A/IRN/22/99 Tabriz, East Azerbaijan Province, Iran  1999 Bovine EF208772
A/IRN/1/2005 Ghalch-Sadri, Qom, Qom Province, Iran  Apr 4, 2005  Bovine EF208769
A22/IRQ/24/64 Mosul, Iraq 1964 Bovine AJ251474
A21/Lumbwa/KEN/64 Lumbwa,  Kenya  1964 Bovine AY593761 
A23/Kitale/KEN/64 Kitale, Kenya 1964 Bovine AY593766 
A/KEN/15/98 Meru, Kenya  Sep 8, 1998  Bovine EF208774
A/KEN/16/98A Nakuru, Kenya  Sep 15, 1998  Bovine EF208775
A/KEN/29/2005 Embu, Eastern Province, Kenya  Aug 24, 2005  Bovine EF208773
A/MAI/2/97 Mali Not known  Not known  EF208776
A15/Bangkok/TAI/60 Bangkok, Thailand 1960 Bovine AY593755 
A/TAI/118/87† Sara Buri, Thailand  1987 Not known  EF208777
A/TAI/2/97 Thailand 1997 Not known EF208778
A12/UK/119/32  Kent, United Kingdom  1932 Bovine AY593752 
*WRLFMD, World Reference Laboratory for Foot-and-Mouth Disease. 
†Not a WRLFMD reference no. Foot-and-Mouth Disease Virus Serotype A, Egypt 
amplicons generated sequences that corresponded to se-
rotype A, identical to the complete VP1 sequences of A/
EGY/1/2006 and A/EGY/2/2006. Together, these ﬁ  ndings 
support the conclusion that FMDV corresponding to a sin-
gle serotype A was present in this material.
For vaccine selection, serologic tests were conducted 
to evaluate the extent of in vitro cross-neutralization of 
A/EGY/1/2006 and A/EGY/2/2006 by antisera produced 
against available FMDV vaccine strains (9). The match (r1 
value) against the vaccine strains A22/Iraq/64 and A/Iran/96 
that are regularly used elsewhere in the Middle East was 
less than the cut-off value of 0.3 (r1 = 0.23 and 0.24, respec-
tively), whereas an acceptable match (r1 = 0.42) was found 
against the A/Eritrea/98 vaccine strain that is of East Afri-
can origin. However, A/Eritrea/98 vaccine is not in routine 
production nor held in vaccine reserves and was therefore 
not available for immediate supply. A recent in vivo study 
demonstrated that a high potency A22/Iraq/64 vaccine could 
provide clinical protection against challenge with the new 
A/EGY/2006 virus (B. Haas, pers. comm., 2006). High-
potency vaccines are known to protect even when relation-
ship values are lower than the normal cut-off values (10).
Conclusions
Local interpretation of agarose-based RT-PCR assays 
and sequence data led the Egyptian authorities to initially 
suspect the involvement of at least 2 serotypes, A and SAT 
2. However, tests performed at the WRLFMD conclusively 
showed the presence of a single serotype, A, in the samples 
received from Egypt. Unofﬁ  cial reports suggest that the 
disease was introduced by animals imported from Ethiopia 
for slaughter (11). This hypothesis is consistent with the 
results of the molecular typing, which suggested a relation 
between strains of Egyptian and East African origin. The 
molecular typing conﬁ  rms only that through the trade in 
live cattle, an East African type A strain was introduced, 
which was not contained at the quarantine station. The ori-
gin of the infection is unclear, since the animals in quaran-
tine may have acquired infection at various points during 
shipment, including possible contaminated pens or other 
animals on board the ship, at the port before loading, or 
in transit from Ethiopia to the port of loading. Veterinary 
inspection of the quarantined animals also detected cases 
of lumpy skin disease (LSD), and possibly the origin of 
the LSD epidemic in Egypt in 2006 may relate to the Ethi-
opian animal trade, which is supported by the reports of 
LSD epidemics in Ethiopia in 2005. Undoubtedly, the lack 
of reporting of disease preimportation or at the quarantine 
stations did not assist the authorities in controlling the dis-
ease. Because imported animals may acquire infection at 
any point up until their arrival, they must be vaccinated and 
tested for the absence of FMDV nonstructural proteins.
Acknowledgments
We thank Keith Sumption for assistance in the preparation 
of this article.
This work was supported by Defra, UK (Reference Labora-
tory Contract and Research Grant nos. SE2921 and SE2935). The 
submission and serotyping of samples were supported by Defra 
and a grant from the FAO European Commission for the Control 
of FMD (MTF/INT/003/EEC). The latter also supported an emer-
gency mission of the World Reference Laboratory to Egypt to 
provide diagnostic support in March 2006. 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 10, October 2007  1595 
Figure 2. Midpoint-rooted neighbor-joining tree showing the 
relationships between the A Egypt 2006 virus isolates and other 
contemporary and reference viruses. Numbers indicate the 
percentage occurrence of the branches by the bootstrap resampling 
method. *Reference number not assigned by the World Reference 
Laboratory for Foot-and-Mouth Disease.
Table 2. Oligonucleotide primers used for RT-PCR and sequencing* 
Primer name  Primer sequence (5′→3′) Sense Gene Position†
A-1C562F TACCAAATTACACACGGGAA  Forward  VP3 3123–3142
A-1C612F TAGCGCCGGCAAAGACTTTGA  Forward  VP3 3173–3193
EUR-2B52R GACATGTCCTCCTGCATCTGGTTGAT  Reverse 2B 3963–3988
NK72 GAAGGGCCCAGGGTTGGACTC Reverse 2A/2B 3897–3917
A-1D523R CGTTTCATRCGCACRAGRA  Reverse VP1 3748–3766
*RT-PCR, reverse transcription–PCR. 
†Position on the genome of A21/Lumbwa/KEN/64 (GenBank accession no. AY593761). DISPATCHES
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